

## Correction: Which Risk Model to Use? Clinical Implications of the ACS MRI Screening Guidelines

In this article (*Cancer Epidemiol Biomarkers Prev* 2013;22:146–9), which was published in the January 2013 issue of *Cancer Epidemiology, Biomarkers & Prevention* (1), the development study for the Tyrer-Cuzick model was incorrectly identified as the Mayo Clinic Benign Breast Disease cohort in the Introduction. The model is correctly identified below. The authors regret the error.

The model is a statistical model based in part on the data obtained from the International Breast Intervention Study (IBIS).

### Reference

1. Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, et al. Which risk model to use? Clinical implications of the ACS MRI screening guidelines. *Cancer Epidemiol Biomarkers Prev* 2013;22:146–9.

Published OnlineFirst May 16, 2013.

doi: 10.1158/1055-9965.EPI-13-0300

©2013 American Association for Cancer Research.